Multiple sclerosis   

Is it dependent on which DMT the patient is on?

Are there emerging biomarkers that help distinguish the phenotypes in the absence of evaluation over time?

E.g., JC virus antibody titer, absolute lymphocyte count, etc.

Are there contraindications to drugs like oxaliplatin or abraxane? Does chronicity or severity of the patient's underlying symptoms play a role in yo...